Program
KT502
A development code.
Its studies are mostly in Arthritis, Rheumatoid, led by Kali Therapeutics.
Furthest: phase 1, since Apr 27, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kali Therapeutics | 11 open or running | phase 1since Apr 27, 2026 | Apr 27, 2026 | Dec 2027phase 1 · NCT07564154 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 27, 2026First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT07564154 · 27 planned · Australia, New Zealand
Ahead
- Dec 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT07564154
TargetBeta
“KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | Kali Therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07564154Arthritis, Rheumatoid · Australia, New Zealand | 1 | Recruiting | Dec 2027 | 27 |
How it is read
Names in the registry
- “KT502”, 1 entry
Codes read as this program: KT502.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.